AKT1 and non-Hodgkin lymphoma: Although we do not know the molecular reasons at this time, combined treatment of NHL cells with 2-DG and inhibitors of the PI3K/AKT pathway, c-MYC and p38 MAPK intracellular signaling pathways may be a promising new therapeutic option.